Fig. 1From: Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanibFlowchart of JCOG1802 (2ND-STEP) study. STS: Soft tissue sarcoma; LPS: Liposarcoma; LMS: Leiomyosarcoma; TRS: Translocation-related sarcoma; IV: Intravenous drip; PO: Per os (Oral administration)Back to article page